NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Study of MK-2225 in Healthy Participants (MK-2225-003)

CompletedPhase 1

Sponsor: Merck Sharp & Dohme LLC

Conditions: Systemic Sclerosis

Interventions: MK-2225, Placebo

Countries: United States

The purpose of the study is to learn about the safety of MK-2225, including how well people tolerate it. Researchers also want to learn what happens to different doses of MK-2225 in a person's body over time.

Eligibility overview

Sex: ALL

Age: 18 Years to 55 Years

Healthy volunteers: Yes

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

The key inclusion criteria include but are not limited to the following:

* Is in good health before randomization
* Body Mass Index (BMI) ≤32 kg/m\^2, inclusive

Exclusion Criteria:

The key exclusion criteria include but are not limited to the following:

* History of clinically significant endocrine, gastrointestinal (GI), cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases
* History of hypersensitivity to the MK-2225 drug substance, its inactive ingredients or the placebo (normal saline)

Locations (2)

Miami, Florida, United States
Springfield, Missouri, United States